Search over 3,000 reports

    Cytomegalovirus (CMV) Infection - Market Insights, Epidemiology and Market Forecast-2023-Global

    Cytomegalovirus (CMV) Infection - Market Insights, Epidemiology and Market Forecast-2023-Global
    Date: Nov, 2017
    Type: Pharmaceutical Industry Report
    Pages: 128
    Geography: Global
    Delivery Timeline: 24 Hours
    SKU: DIMI0014
    DelveInsight's "Cytomegalovirus (CMV) Infection - Market Insights, Epidemiology and Market Forecast-2023" Report provides an overview of the disease and market size of the CMV for theglobal, United States, EU5 (France, Germany, Italy, Spain and United Kingdom) and Japan for 2013-2023. It also includes global historical and forecasted epidemiological data for the CMV Prevalent, Diagnosed and Treatable Cases, CMV Patients among Transplants, Infants Patients at High Risk of CMV and HIV Patients at High Risk of CMVfrom 2013-2023. According to DelveInsight, the Global Diagnosed cases for Cytomegalovirus (CMV) Infection are expected to increase at a CAGR of 0.047% to 172,864 cases in 2023. Cytomegalovirus (CMV) infection is caused by Cytomegalovirus (CMV), a member of the herpes virus family. Upon initial infection, CMV infects the epithelial cells of the salivary gland, resulting in a persistent infection and viral shedding. Person can be infected with CMV at any point of time in life and is not easily diagnosed as no symptoms are shown.
    As per DelveInsight's estimation, the global market size of Cytomegalovirus (CMV) infection shall reach to USD 1,210.4 Million by the end of 2023. The market size for Prophylaxis is expected to grow at a CAGR 6.57% from 2013-2023, while the sales for the therapeutic shall increase at a CAGR of 3.44% from the 2013-2023.
    The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
    Scope
    - Report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options.
    - Marketed information including available prescription drugs.
    - The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5 and Japan from 2013-2023.
    - It also provides Market size of Cytomegalovirus (CMV) infection for United States, EU5 and Japan from 2013 and forecasted Market size to 2023.
    Cytomegalovirus Infections
    Disease Overview
    Symptoms of cytomegalovirus (CMV) Infection
    Etiology
    Risk Factors
    Pathogenesis of human cytomegalovirus
    Pathophysiology of cytomegalovirus infection
    Diagnosis
    Treatment Algorithm for Cytomegalovirus Infections
    Treatment for Congenital CMV Infection
    Treatment of Ganciclovir resistant CMV
    Treatment Guidelines
    Recommendations for Treating Cytomegalovirus Infections
    Disease Management
    Epidemiology and Patient Population
    Global
    Global CMV Prevalent, Diagnosed and Treatable Cases
    United States
    Assumptions and Rationale
    Total CMV Prevalent, Diagnosed and Treatable Cases
    CMV Patients among Transplants
    Infants Patients at High Risk of CMV
    HIV Patients at High Risk of CMV
    Europe
    Italy
    Assumptions and Rationale
    Total CMV Prevalent, Diagnosed and Treatable Cases
    CMV Patients among Transplants
    Infants Patients at High Risk of CMV
    HIV Patients at High Risk of CMV
    Spain
    Assumptions and Rationale
    Total CMV Prevalent, Diagnosed and Treatable Cases
    CMV Patients among Transplants
    Infants Patients at High Risk of CMV
    HIV Patients at High Risk of CMV
    United Kingdom
    Assumptions and Rationale
    Total CMV Prevalent, Diagnosed and Treatable Cases
    CMV Patients among Transplants
    Infants Patients at High Risk of CMV
    HIV Patients at High Risk of CMV
    Germany
    Assumptions and Rationale
    Total CMV Prevalent, Diagnosed and Treatable Cases
    CMV Patients among Transplants
    Infants Patients at High Risk of CMV
    HIV Patients at High Risk of CMV
    France
    Assumptions and Rationale
    Total CMV Prevalent, Diagnosed and Treatable Cases
    CMV Patients among Transplants
    Infants Patients at High Risk of CMV
    HIV Patients at High Risk of CMV
    Japan
    Assumptions and Rationale
    Total CMV Prevalent, Diagnosed and Treatable Cases
    CMV Patients among Transplants
    Infant Patients at High Risk of CMV
    HIV Patients at High Risk of CMV in Japan
    Unmet Medical Needs
    Marketed Products
    Valcyte (Valganciclovir hydrochloride)
    Advantages & Disadvantages
    Product Profile
    Efficacy
    Safety
    Side effects of Drug
    SWOT Analysis
    FOSCAVIR (foscarnet sodium)
    Advantages & Disadvantages
    Product Profile
    Efficacy
    Safety
    Side effects of Drug
    SWOT Analysis
    CytoGam (Cytomegalovirus Immune Globulin Intravenous-Human)
    Advantages & Disadvantages
    Product Profile
    Efficacy
    Safety
    Side effects of Drug
    SWOT Analysis
    CytoTect CP
    Advantages & Disadvantages
    Product Profile
    Efficacy
    Safety
    Side effects of Drug
    SWOT Analysis
    Valtrex (Valacyclovir hydrochloride)
    Advantages & Disadvantages
    Product Profile
    Efficacy
    Safety
    Side effects of Drug
    SWOT Analysis
    Emerging Products Analysis
    Emerging Therapies
    1. Approved Products
    Cytovir CMV: Cell Medica Ltd.
    Product Description
    Research and Development
    Product Development Activities
    2. Pipeline Products (Phase III)
    CytoTect CP 70: Biotest AG.
    Product Description
    Advantages & Disadvantages
    Research and Development
    Product Development Activities
    Letermovir: Merck & Co.
    Product Description
    Advantages & Disadvantages
    Research and Development
    Product Development Activities
    Brincidofovir: Chimerix Inc.
    Product Description
    Advantages & Disadvantages
    Research and Development
    Product Development Activities
    ASP0113: Astellas Pharma Global Development, Inc.
    Product Description
    Advantages & Disadvantages
    Research and Development
    Product Development Activities
    Human Cytomegalovirus Immune Globulin: CSL Behring
    Product Description
    Advantages & Disadvantages
    Research and Development
    Product Development Activities
    Global Market Size
    United States
    Europe
    Italy
    Germany
    France
    Spain
    United Kingdom
    Japan
    Market Drivers
    Market Barriers
    Appendix
    Report Methodology
    Consulting Services
    Disclaimer
    About DelveInsight
    Table 1: Total CMV Prevalent, Diagnosed and Treatable Cases (2013-2023)
    Table 2: Total CMV Prevalent, Diagnosed and Treatable Cases for United States (2013-2023)
    Table 3: CMV Patients among Transplants in United States (2013-2023)
    Table 4: Infants Patients at High Risk of CMV in United States (2013-2023)
    Table 5: HIV Patients at High Risk of CMV in United States (2013-2023)
    Table 6 Total CMV Prevalent, Diagnosed and Treatable Cases for Italy (2013-2023)
    Table 7: CMV Patients among Transplants in Italy (2013-2023)
    Table 8: Infants Patients at High Risk of CMV in Italy (2013-2023)
    Table 9: HIV Patients at High Risk of CMV in Italy (2013-2023)
    Table 10: Total CMV Prevalent, Diagnosed and Treatable Cases for Spain (2013-2023)
    Table 11: CMV Patients among Transplants in Spain (2013-2023)
    Table 12: Infants Patients at High Risk of CMV in Spain (2013-2023)
    Table 13: HIV Patients at High Risk of CMV in Spain (2013-2023)
    Table 14: Total CMV Prevalent, Diagnosed and Treatable Cases for United Kingdom (2013-2023)
    Table 15: CMV Patients among Transplants in United Kingdom (2013-2023)
    Table 16: Infants Patients at High Risk of CMV in United Kingdom (2013-2023)
    Table 17: HIV Patients at High Risk of CMV in United Kingdom (2013-2023)
    Table 18: Total CMV Prevalent, Diagnosed and Treatable Cases for Germany (2013-2023)
    Table 19: CMV Patients among Transplants in Germany (2013-2023)
    Table 20: Infants Patients at High Risk of CMV in Germany (2013-2023)
    Table 21: HIV Patients at High Risk of CMV in Germany (2013-2023)
    Table 22: Total CMV Prevalent, Diagnosed and Treatable Cases for France (2013-2023)
    Table 23: CMV Patients among Transplants in France (2013-2023)
    Table 24: Infants Patients at High Risk of CMV in France (2013-2023)
    Table 25: HIV Patients at High Risk of CMV in France (2013-2023)
    Table 26: Total CMV Prevalent, Diagnosed and Treatable Cases for Japan (2013-2023)
    Table 27: CMV Patients among Transplants in Japan (2013-2023)
    Table 28: Infants Patients at High Risk of CMV in Japan (2013-2023)
    Table 29: HIV Patients at High Risk of CMV in Japan (2013-2023)
    Table 30: Total Market size of Cytomegalovirus (CMV) Infection USD, Million(2013-2023)
    Table 31: Total Market size of Cytomegalovirus (CMV) Infection USD, Million(2013-2023)
    Table 32: Total Market size of Cytomegalovirus (CMV) Infection USD, Million(2013-2023)
    Table 33: Total Market size of Cytomegalovirus (CMV) Infection USD, Million(2013-2023)
    Table 34: Total Market size of Cytomegalovirus (CMV) Infection USD, Million(2013-2023)
    Table 35: Total Market size of Cytomegalovirus (CMV) Infection USD, Million (2013-2023)
    Table 36: Total Market size of Cytomegalovirus (CMV) Infection USD, Million(2013-2023)
    Table 37: Total Market size of Cytomegalovirus (CMV) Infection USD, Million(2013-2023)
    Figure 1: Risk Factors CMV infection, 2017
    Figure 2: Total CMV Prevalent, Diagnosed and Treatable Cases (2013-2023)
    Figure 3: Total CMV Prevalent, Diagnosed and Treatable Cases for United States (2013-2023)
    Figure 4: CMV Patients among Transplants in United States (2013-2023)
    Figure 5: Infants Patients at High Risk of CMV in United States (2013-2023)
    Figure 6: HIV Patients at High Risk of CMV in United States (2013-2023)
    Figure 7: Total CMV Prevalent, Diagnosed and Treatable Cases for Italy (2013-2023)
    Figure 8: CMV Patients among Transplants in Italy (2013-2023)
    Figure 9: Infants Patients at High Risk of CMV in Italy (2013-2023)
    Figure 10: HIV Patients at High Risk of CMV in Italy (2013-2023)
    Figure 11: Total CMV Prevalent, Diagnosed and Treatable Cases for Spain (2013-2023)
    Figure 12: CMV Patients among Transplants in Spain (2013-2023)
    Figure 13: Infants Patients at High Risk of CMV in Spain (2013-2023)
    Figure 14: HIV Patients at High Risk of CMV in Spain (2013-2023)
    Figure 15: Total CMV Prevalent, Diagnosed and Treatable Cases for United Kingdom (2013-2023)
    Figure 16: CMV Patients among Transplants in United Kingdom (2013-2023)
    Figure 17: Infants Patients at High Risk of CMV in United Kingdom (2013-2023)
    Figure 18: HIV Patients at High Risk of CMV in United Kingdom (2013-2023)
    Figure 19: Total CMV Prevalent, Diagnosed and Treatable Cases for Germany (2013-2023)
    Figure 20: CMV Patients among Transplants in Germany (2013-2023)
    Figure 21: Infants Patients at High Risk of CMV in Germany (2013-2023)
    Figure 22: HIV Patients at High Risk of CMV in Germany (2013-2023)
    Figure 23: Total CMV Prevalent, Diagnosed and Treatable Cases for France (2013-2023)
    Figure 24: CMV Patients among Transplants in France (2013-2023)
    Figure 25: Infants Patients at High Risk of CMV in France (2013-2023)
    Figure 26: HIV Patients at High Risk of CMV in France (2013-2023)
    Figure 27: Total CMV Prevalent, Diagnosed and Treatable Cases for Japan (2013-2023)
    Figure 28: CMV Patients among Transplants in Japan (2013-2023)
    Figure 29: Infants Patients at High Risk of CMV in Japan (2013-2023)
    Figure 30: HIV Patients at High Risk of CMV in Japan (2013-2023)
    Figure 31: Total Market Size of Cytomegalovirus (CMV) Infection in USD, Million(2013-2023)
    Figure 32: US Market Size of Cytomegalovirus (CMV) Infection in USD, Million(2013-2023)
    Figure 33: Italy market size of Cytomegalovirus (CMV) Infection in USD, Million(2013-2023)
    Figure 34: Germany market size of Cytomegalovirus (CMV) Infection in USD, Million (2013-2023)
    Figure 35: France market size of Cytomegalovirus (CMV) Infection in USD, Million(2013-2023)
    Figure 36: Spain market size of Cytomegalovirus (CMV) Infection in USD, Million(2013-2023)
    Figure 37: UK market size of Cytomegalovirus (CMV) Infection in USD, Million(2013-2023)
    Figure 38: Japan market size of Cytomegalovirus (CMV) Infection in USD, Million(2013-2023)
    Cytomegalovirus (CMV) Infection Market (7MM)

    Cytomegalovirus (CMV) Infection Market forecasting

    Cytomegalovirus (CMV) Infection Sales forecasting

    Cytomegalovirus (CMV) Infection Market segments

    Cytomegalovirus (CMV) Infection Epidemiology

    Cytomegalovirus (CMV) Infection Pipeline products and technologies

    Cytomegalovirus (CMV) Infection Competitive landscape

    Cytomegalovirus (CMV) Infection SWOT analysis

    Cytomegalovirus (CMV) Infection Market Driver's and barriers

    Cytomegalovirus (CMV) Infection Key Companies and Funding

    • Single User License
      (20% Off)
      $4,950.00
      $3960
    • Site License
      (30% Off)
      $9,900.00
      $6930
    • Global License
      (40% Off)
      $14,850.00
      $8910

    Contact Us

    Phone
    +91-11-45689769, +91 9650213330

    Email
    info@delveinsight.com

    Address
    New Delhi-110075, India

    Latest Tweets

    • Copyright © 2017 Delveinsight.
    • Sitemap